Nuance Investments LLC reduced its position in Globus Medical Inc (NYSE:GMED) by 87.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 98,439 shares of the medical device company’s stock after selling 678,480 shares during the period. Nuance Investments LLC’s holdings in Globus Medical were worth $4,046,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in Globus Medical by 1.4% in the 2nd quarter. Vanguard Group Inc. now owns 5,712,043 shares of the medical device company’s stock valued at $189,355,000 after buying an additional 76,345 shares during the last quarter. Janus Henderson Group PLC boosted its position in Globus Medical by 18.6% in the 3rd quarter. Janus Henderson Group PLC now owns 3,181,499 shares of the medical device company’s stock valued at $94,554,000 after buying an additional 498,187 shares during the last quarter. State Street Corp boosted its position in Globus Medical by 5.8% in the 2nd quarter. State Street Corp now owns 2,376,667 shares of the medical device company’s stock valued at $78,789,000 after buying an additional 129,939 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Globus Medical by 1.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,843,340 shares of the medical device company’s stock valued at $54,784,000 after buying an additional 32,034 shares during the last quarter. Finally, NWQ Investment Management Company LLC purchased a new position in Globus Medical in the 3rd quarter valued at about $25,856,000. 69.67% of the stock is owned by institutional investors.

A number of research firms have weighed in on GMED. Barclays reissued a “sell” rating and issued a $36.00 price objective on shares of Globus Medical in a research report on Wednesday, January 10th. Zacks Investment Research raised shares of Globus Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Wells Fargo & Co reissued an “outperform” rating and issued a $51.00 price objective (up from $46.00) on shares of Globus Medical in a research report on Wednesday, January 10th. BTIG Research restated a “buy” rating and issued a $37.00 target price on shares of Globus Medical in a research note on Thursday, November 9th. Finally, Needham & Company LLC restated a “hold” rating on shares of Globus Medical in a research note on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $40.57.

Shares of Globus Medical Inc (GMED) opened at $45.28 on Wednesday. The stock has a market cap of $4,360.00, a PE ratio of 41.16, a PEG ratio of 2.64 and a beta of 0.48. Globus Medical Inc has a 12 month low of $26.63 and a 12 month high of $47.09.

In other news, Director David D. Davidar sold 55,383 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $40.66, for a total value of $2,251,872.78. Following the sale, the director now owns 752,236 shares in the company, valued at approximately $30,585,915.76. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Steven Payne sold 3,076 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $39.30, for a total transaction of $120,886.80. Following the completion of the sale, the chief accounting officer now owns 23,847 shares in the company, valued at approximately $937,187.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 73,459 shares of company stock worth $2,947,260. Company insiders own 28.21% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2018/02/14/nuance-investments-llc-has-4-05-million-holdings-in-globus-medical-inc-gmed.html.

Globus Medical Profile

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical Inc (NYSE:GMED).

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.